NASDAQ · SYRE
Spyre Therapeutics, Inc.
$96.27-$2.69 (-2.72%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.63% below the high.
Loading market information…
NASDAQ · ALRN · USD
Stock price, earnings
Quote as of Jan 10, 2025, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aileron Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aileron Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aileron Therapeutics, Inc. is a U.S.-based clinical-stage company specializing in chemoprotection oncology. Its primary therapeutic candidate, ALRN-6924, is currently being evaluated across multiple clinical trials for various cancer types. These include a Phase 1 trial for solid tumors and lymphoma, a Phase 2a clinical trial targeting peripheral T-cell lymphoma, and a Phase I trial for acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Furthermore, ALRN-6924 is involved in combination studies: a Phase 1b trial testing its efficacy with cytarabine (Ara-C) in patients with MDS, and a Phase 2a combination trial with palbociclib for individuals with tumors exhibiting MDM2 amplifications co-amplifications, as well as for those with p53-mutated small cell lung cancer (the latter having already completed its Phase 1b clinical assessment). The company maintains license agreements with institutions such as the Dana-Farber Cancer Institute, Harvard College, and Umicore Precious Metals Chemistry USA, LLC. Established in 2001, the Boston, Massachusetts-headquartered firm was originally known as Renegade Therapeutics, Inc. before rebranding to Aileron Therapeutics, Inc. in February 2007.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:29 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$96.27-$2.69 (-2.72%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.63% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
$9.81+$0.39 (+4.14%)
AlloVir, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.38% below the high.
$4.97$0.00 (0.0%)
bluebird bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 82.62% below the high.
$0.78+$0.01 (+1.3%)
ERYTECH Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.01% below the high.
$0.30-$0.00 (-0.03%)
GreenLight Biosciences Holdings’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
$0.70-$0.06 (-7.74%)
Magenta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.35% below the high.
$1.00-$0.03 (-2.91%)
Pluristem Therapeutics Inc.: Healthcare · Biotechnology.
